Cabozantinib Post First-line Immuno-oncology Checkpoint Inhibitor Containing Combination (CARINA)

Ipsen

Status: Completed

Conditions: Advanced Renal Cell Carcinoma (aRCC)

Study type: Observational

Funder types: Industry

Identifiers

NCT04957160

CLIN-60000-451

Details and patient eligibility

About

This study will collect real-world data for the new treatment pathways for all patients with Advanced Renal Cell Carcinoma (ARCC) who were treated with a 1L IO (first-line, Immuno-Oncology checkpoint inhibitor) combination therapy and progressed to a 2L treatment with particular focus to understanding where cabozantinib is prescribed after 1L IO containing combination therapy.

Enrollment: 281 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients with a diagnosis of aRCC.
• Patients aged ≥18 years at aRCC diagnosis treated with a 1L IO containing combination therapy who have progressed to a 2L treatment.

Exclusion criteria

• Patient's hospital medical records are unavailable for review;
• Patients have started a 2L treatment as part of a Renal Carcinoma Treatment (RCT).

Trial design

281 participants in 2 patient groups

Cohort 1

Cohort 2